| | SAN DIEGO, Feb. 10, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. ,(NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will host a virtual R&D Day at 10:00 am - 2:00 pm ET / 7:00 - 11:00 am PT on Wednesday, February 24, 2021. 
Poseida’s R&D Day will feature presentations and an interactive Q&A session from the Company’s executive leadership team as well as presenters Dr. Bruce Scharschmidt, an expert in liver disease and urea cycle disorders and a consultant on Poseida’s liver directed gene therapies; and Denise Sabatino, Ph.D., University of Pennsylvania, Children’s Hospital of Philadelphia, an expert in hemophilia gene therapy. The event will focus on Poseida’s novel cell and gene engineering platform technologies, differentiated CAR-T programs and innovative approaches to cell and gene therapy. Speakers will also discuss Poseida’s current programs, new advances and strategies for 2021 and beyond. A live webcast will be available on the Investors & Media section of Poseida’s website, www.poseida.com. A replay of the webcast will be available for 30 days following the presentation. About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Modification System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit www.poseida.com and connect with us on Twitter and LinkedIn. Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding the clinical data presented, the potential benefits of Poseida’s technology platforms and product candidates and Poseida’s plans and strategy with respect to developing its technologies and product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry, the fact that future clinical results could be inconsistent with results observed to date and the other risks described in Poseida’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.  View original content to download multimedia:http://www.prnewswire.com/news-releases/poseida-therapeutics-to-host-virtual-rd-day-on-february-24-2021-301225393.html
SOURCE Poseida Therapeutics, Inc. | |
